CD160 receptor in CLL: Current state and future avenues

Area of Science:

• Immunology
• Oncology
• Hematology

Background:

• CD160 is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein found on cytotoxic natural killer (NK) cells and T-cell subsets.
• It plays a key role in NK-cell cytotoxicity, cytokine production, and immune system modulation.
• Aberrant CD160 expression is observed in B-cell chronic lymphocytic leukemia (CLL) but not in normal B lymphocytes.

Purpose of the Study:

• To review the role of CD160 in the pathophysiology of B-cell chronic lymphocytic leukemia (CLL).
• To discuss the potential of CD160 as a prognostic marker for minimal residual disease (MRD) in CLL.

Main Methods:

• Literature review focusing on CD160 expression and function in CLL.
• Analysis of CD160's involvement in tumor cell proliferation and apoptosis resistance.
• Evaluation of CD160 as a prognostic indicator for MRD detection in CLL.

Main Results:

• CD160 expression in CLL enhances tumor cell proliferation and resistance to apoptosis.
• CD160 is not expressed in normal B lymphocytes, indicating its aberrant role in CLL.
• CD160 shows potential as a prognostic marker for MRD assessment in CLL.

Conclusions:

• CD160 plays a significant role in the pathophysiology of CLL.
• CD160 is a promising prognostic marker for MRD detection, aiding in clinical management and remission achievement in CLL.